Handbook of Bioequivalence Testing
Preview
Book Description
As the generic pharmaceutical industry continues to grow and thrive, so does the need to conduct adequate, efficient bioequivalence studies. In recent years, there have been significant changes to the statistical models for evaluating bioequivalence. In addition, advances in the analytical technology used to detect drug and metabolite levels have made bioequivalence testing more complex. The second edition of Handbook of Bioequivalence Testing has been completely updated to include the most current information available, including new findings in drug delivery and dosage form design and revised worldwide regulatory requirements.
New topics include:
- A historical perspective on generic pharmaceuticals
- New guidelines governing submissions related to bioequivalency studies, along with therapeutic code classifications
- Models of noninferiority
- Biosimilarity of large molecule drugs
- Bioequivalence of complementary and alternate medicines
- Bioequivalence of biosimilar therapeutic proteins and monoclonal antibodies
- New FDA guidelines for bioanalytical method validation
- Outsourcing and monitoring of bioequivalence studies
The cost of generic drugs is rising much faster than in the past, partly because of the increased costs required for approval—including those for bioequivalence testing. There is a dire need to re-examine the science behind this type of testing to reduce the burden of development costs—allowing companies to develop generic drugs faster and at a lower expense. The final chapter explores the future of bioequivalence testing and proposes radical changes in the process of biowaivers. It suggests how the cost of demonstrating bioequivalence can be reduced through intensive analytical investigation and proposes that regulatory agencies reduce the need for bioequivalence studies in humans. Backed by science and updated with the latest research, this book is destined to spark continued debate on the efficacy of the current bioequivalence testing paradigm.
Table of Contents
Historical Perspective on Generic Pharmaceuticals
Physicochemical Basis of Bioequivalence Testing
Drug Delivery Factors
Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling
Bioequivalence Testing Rationale and Principles
Bioequivalence Waivers
Statistical Evaluation of Bioequivalence Data
Regulatory Inspection Process
Fed Bioequivalence Studies
Topical Drugs
Bioequivalence of Nasal Products
Bioequivalence of Complementary and Alternate Medicines
Bioequivalence of Biosimilar Products
Bioequivalence Testing: The US Perspective
Bioequivalence Testing: European Perspective
Bioequivalence Testing: The ROW Perspective
Bioequivalence Testing Protocols
Bioequivalence Documentation
Good Laboratory Practices
Bioanalytical Method Validation
Good Clinical Practice
Computer and Software Validation
Outsourcing and Monitoring of Bioequivalence Studies
Epilogue: Future of Bioequivalence Testing
Appendix A: Glossary of Terms
Appendix B: Dissolution Testing Requirements for US FDA Submission
Bibliography
Index
Author(s)
Biography
Sarfaraz K. Niazi, PhD, is the chairman and CEO of Therapeutic Proteins International, a world-class developer and manufacturer of biosimilar recombinant drugs. The company now leads the world in using innovative methods of manufacturing biosimilar recombinant drugs coming off-patents. He employs hundreds of world’s top scientists working toward the goal of making life-saving biological drugs more affordable. He has published over 100 refereed research articles and abstracts, dozens of books, and hundreds of literary writings that span the vast areas of poetry, philosophy, rhetoric, irony, and modern dilemma.
Reviews
"This handbook offers a complete description of every aspect of bioequivalence testing … [It] is an essential, one-of-a-kind resource for anyone interested in bioequivalence. There are no other books that compile so many aspects in one place."
—Jennifer L. Colon, PharmD, Temple University School of Pharmacy, in Doody’s Review Service